Detection of minimal residual disease in cerebro-spinal fluid of a patient with acute myelogenous leukemia with t(16;21)(p11;q22) translocation by reverse transcriptase-polymerase chain reaction.
We describe a patient with acute myelogenous leukemia (AML) with t(16;21)(p11;q22) translocation, whose minimal residual disease (MRD) both in cerebrospinal fluid (CSF) and bone marrow (BM) was monitored by reverse transcriptase-polymerase chain reaction (RT-PCR). A TLS/ERG-FUS fusion transcript, which is known to be expressed by t(16;21)(p11;q22) translocation, was detectable by RT-PCR both in BM and CSF cells in the first complete remission, suggesting the existence of MRD. The disease relapsed 6 months after its onset and allogeneic peripheral blood stem cell transplantation (PBSCT) was undergone. A TLS/ERG-FUS fusion transcript became rapidly below the detection level after PBSCT. These findings suggest the usefulness of RT-PCR for the detection of MRD in CSF, which contains a limited number of cells, as well as BM.
Harigae
H
H
Department of Internal Medicine, Suifu Hospital, Ibaraki, Japan.
Kobayashi
M
M
Mihara
A
A
Watanabe
N
N
D000328:Adult; D001853:Bone Marrow / Q000473:pathology; D017690:Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000134:cerebrospinal fluid* / Q000235:genetics* / Q000473:pathology; D008297:Male; D016133:Polymerase Chain Reaction; D012008:Recurrence; D033581:Stem Cell Transplantation; D014178:Translocation, Genetic